Breakthrough Treatment for Incurable Breast Cancer Receives Official Acceptance by Chinese Drug Administration

In a significant development for the medical community, a cutting-edge therapy known as "TROP 2 ADC" has achieved formal acceptance by the China Drug Administration (CDE) for the treatment of advanced breast cancer. Developed through a collaboration between Daiichi Sankyo and AstraZeneca, this innovative drug, named datopotamab deruxtecan (Dato-DXd), has demonstrated remarkable efficacy in clinical trials, offering renewed hope to patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Promising Clinical Results:

The approval comes on the heels of compelling findings from the global Phase III clinical trial, TROPION-Breast01, which showcased the superior performance of datopotamab deruxtecan in patients who had previously undergone endocrine therapy. The study illustrated a median progression-free survival (PFS) of 6.9 months, representing a significant 37% reduction in the risk of disease progression or death compared to standard chemotherapy. At the same time, datopotamab deruxtecan exhibited an objective response rate (ORR) of 36.4%, surpassing the chemotherapy group's rate of 22.9%.

Revolutionary Targeted Therapy:

Datopotamab deruxtecan is an innovative antibody-drug conjugate (ADC) that employs a unique technology designed to specifically target the TROP2 receptor. Following the success of trastuzumab deruxtecan, this ADC represents Daiichi Sankyo's second groundbreaking drug to be submitted for approval in China. By leveraging its DXd payload, datopotamab deruxtecan delivers potent anti-cancer agents directly to tumor cells, maximizing treatment efficacy while minimizing systemic side effects.

Addressing Unmet Medical Needs:

The new drug application seeks to address the pressing medical need for effective treatments in patients with incurable or metastatic HR+/HER2- breast cancer who have previously received systemic therapy. By offering a viable therapeutic option, datopotamab deruxtecan aims to prolong the survival and improve the quality of life of adult patients who are not eligible for curative surgery.

Ongoing Research and Safety Profile:

Ongoing investigations are being conducted to evaluate the drug's impact on overall survival (OS), with encouraging trends observed in the interim analysis. Importantly, datopotamab deruxtecan has exhibited a favorable safety profile, with no new safety concerns identified during the clinical trials. The incidence of treatment-related adverse events of grade 3 or higher was only 21% in the datopotamab deruxtecan group, half the rate observed in the chemotherapy group (45%).

The acceptance of the new drug application for datopotamab deruxtecan marks a significant milestone in the treatment of HR+/HER2- breast cancer. With its remarkable efficacy and favorable safety profile, this targeted therapy offers a ray of hope for patients facing limited treatment options. As the development of novel cancer therapies continues to advance, datopotamab deruxtecan represents a promising breakthrough in the fight against incurable breast cancer, paving the way for improved patient outcomes and a brighter future in oncology.